Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDV09U
|
|||
| Drug Name |
DS-1558
|
|||
| Synonyms |
1202575-67-4; CHEMBL3427712; (S)-3-ethoxy-3-(4-(((R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)propanoic acid; SCHEMBL1508316; BDBM50085568; SB18922; (3S)-3-ethoxy-3-[4-[[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]propanoic acid; (3S)-3-Ethoxy-3-[4-[[(R)-4-(trifluoromethyl)-2,3-dihydro-1H-indene-1alpha-yl]oxy]phenyl]propanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21F3O4
|
|||
| Canonical SMILES |
CCOC(CC(=O)O)C1=CC=C(C=C1)OC2CCC3=C2C=CC=C3C(F)(F)F
|
|||
| InChI |
1S/C21H21F3O4/c1-2-27-19(12-20(25)26)13-6-8-14(9-7-13)28-18-11-10-15-16(18)4-3-5-17(15)21(22,23)24/h3-9,18-19H,2,10-12H2,1H3,(H,25,26)/t18-,19+/m1/s1
|
|||
| InChIKey |
YHLQVQKZDZYMIP-MOPGFXCFSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free fatty acid receptor 1 (GPR40) | Target Info | Agonist | [2] |
| KEGG Pathway | Insulin secretion | |||
| Reactome | G alpha (q) signalling events | |||
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Incretin Synthesis, Secretion, and Inactivation | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. | |||
| REF 2 | Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan 13;6(3):266-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.